Nurix presents data on bexobrutideg for chronic urticaria at dermatology meeting
Tweet Send to a Friend
Nurix Therapeutics (NASDAQ: NRIX) presented preclinical and Phase 1 data for bexobrutideg (NX-5948) in chronic spontaneous urticaria at the 2026 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
